Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of Zefamenib combined with chemotherapy or targeted Agents in patients with Acute Myeloid Leukemia

Haiping Dai, Depei Wu, Suning Chen, Yu Wang

Blood (2025) 146 (Supplement 1): 8257.

https://doi.org/10.1182/blood-2025-8257

Published: 2025

Journal Articles

Ivosidenib combined with venetoclax and azacitidine for the treatment of newly diagnosed IDH1-mutant Acute Myeloid Leukemia: A prospective, two cohorts, multicenter study

Haiping Dai, Depei Wu, Suning Chen

Blood (2025) 146 (Supplement 1): 8249.

https://doi.org/10.1182/blood-2025-8249

Published: 2025

Journal Articles

Clinical features and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia: A 15-year retrospective study

Yiyan Zhu, Wenzhi CAI, Xueqing Dou, Ying Wang, Xiaofei Yang, Haiping Dai, Depei Wu, Suning Chen

Blood (2025) 146 (Supplement 1): 5103.

https://doi.org/10.1182/blood-2025-5103

Published: 2025

Journal Articles

Safety and efficacy of low-intensity chemotherapy combined with sequential blinatumomab and inotuzumab ozogamicin immunotherapy in newly diagnosed B-ALL patients unfit/fit-declined for intensive chemotherapy: A prospective, open-label, single-arm Phase II trial in progress

Shenhao Liu, Chongsheng Qian, Haiping Dai, Lan Dai, Yanjun Wu, Zhen Yao, Zheng Li, Wenjie Gong, Aining Sun, Depei Wu, Shengli Xue

Blood (2025) 146 (Supplement 1): 3358.

https://doi.org/10.1182/blood-2025-3358

Published: 2025

Journal Articles

Auto-HSCT combined with blinatumomab as an allo-HSCT-sparing strategy in newly diagnosed B-ALL: Phase II trial results

Zihao Wang, Chongsheng Qian, Zhen Yao, Zheng Li, Wenjie Gong, Haiping Dai, Yanjun Wu, Kai-Wen Tan, Fangtong Liu, Chao-Ling Wan, Depei Wu, Shengli Xue

Blood (2025) 146 (Supplement 1): 3349.

https://doi.org/10.1182/blood-2025-3349

Published: 2025

Journal Articles

Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFβ::MYH11(+) acute myeloid leukemia

Ziyu Feng, Jia Chen, Haiping Dai, Xiaohui Hu, Yang Xu, Shengli Xue, Huiying Qiu, Xiaowen Tang, Han Yue, Suning Chen, Depei Wu, Ying Wang

Blood (2025) 146 (Supplement 1): 1674.

https://doi.org/10.1182/blood-2025-1674

Published: 2025

Journal Articles

Venetoclax, cladribine plus low-dose cytarabine for relapsed/refractory Acute Myeloid Leukemia: A multicenter, randomized phase II Study

Han-Yu Cao, Fangtong Liu, Kai-Wen Tan, Zi-Hao Wang, Si-Man Huang, Chao-Ling Wan, Yuan-Hong Huang, Mei-Jing Liu, Zhen Yao, Zheng Li, Ming-Zhu Xu, Hai-Xia Zhou, Haiping Dai, Shengli Xue

Blood (2025) 146 (Supplement 1): 5202.

https://doi.org/10.1182/blood-2025-5202

Published: 2025

Journal Articles

Bgb-11417: A novel BCL2 inhibitor with robust antileukemic activity in T-cell acute lymphoblastic leukemia, alone or with vincristine

Hongfeng Pang, Chao-Ling Wan, Yuan-Hong Huang, Shuaishuai Ge, Chengqiao Qiu, Songbai Liu, Depei Wu, Haiping Dai, Shengli Xue

Blood (2025) 146 (Supplement 1): 6813.

https://doi.org/10.1182/blood-2025-6813

Published: 2025

Journal Articles

Enhanced homing and infiltration capabilities of CI9 cells improve treatment efficacy for T-cell acute lymphoblastic leukemia with extramedullary involvement

Jinfeng Ma, Depei Wu, Nan Xu, Haiping Dai, Liqing Kang, Jingwen Tan, Haiguo Zhang, Ling Ye, Lei Yu, Xu Jia, Shengli Xue

Blood (2025) 146 (Supplement 1): 7643.

https://doi.org/10.1182/blood-2025-7643

Published: 2025

Journal Articles

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial

Yue Zhou, Juan Chen, Qingya Cui, Haiping Dai, Zheng Li, Jia Yin, Wei Cui, Mengyun Li, Xuekai Li, Xin Zhang, Feiran Gong, Xiaming Zhu, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2024-199119

Published: 2024

Journal Articles

Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial

Jia Yin, Qingya Cui, Haiping Dai, Zheng Li, Liqing Kang, Wei Cui, Xiaopeng Tian, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 4836.

https://doi.org/10.1182/blood-2024-207197

Published: 2024

Journal Articles

Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

Yunju Ma, Qingya Cui, Chunxiu Yang, Wei Cui, Mengyun Li, Zheng Li, Haiping Dai, Liqing Kang, Lei Yu, Zaixiang Tang, Jianxin Fu, Min Jiang, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 683.

https://doi.org/10.1182/blood-2024-209249

Published: 2024

Journal Articles

Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

Blood (2024) 144 (Supplement 1): 971.

https://doi.org/10.1182/blood-2024-202801

Published: 2024

Journal Articles

Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Fangtong Liu, Chao-Ling Wan, Yu-Qing Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Shuai-Shuai Ge, Miao Wang, Mei-Jing Liu, Zihao Wang, Sheng-Li Xue, Haiping Dai

Blood (2024) 144 (Supplement 1): 1484.

https://doi.org/10.1182/blood-2024-202500

Published: 2024

Journal Articles

Safety and Efficacy of Blinatumomab and Auto-HSCT “Sandwich” Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia

Chong-Sheng Qian, Zihao Wang, Lan Dai, Li Yao, Zhen Yao, HaiXia Zhou, Mingzhu Xu, Wenjie Gong, Zheng Li, Haiping Dai, Aining Sun, Depei Wu, Shengli Xue

Blood (2024) 144 (Supplement 1): 5878.

https://doi.org/10.1182/blood-2024-205115

Published: 2024

Journal Articles

Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Chao-Ling Wan, Yu-Qing Liu, Fang-Tong Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Zihao Wang, Shuai-Shuai Ge, Miao Wang, Haiping Dai, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 1527.

https://doi.org/10.1182/blood-2024-197933

Published: 2024

Journal Articles

Sitagliptin for Prophylaxis of aGVHD in Alternative Donor Transplantations: Updated Results of 2 Years Follow-up of a Superiority, Randomized Controlled Phase III Trial

Man Qiao, Suning Chen, Ying Wang, Shengli Xue, Xiaofei Yang, Depei Wu, Huiying Qiu, Yue Han, Yanming Zhang, Kourong Miao, Jihao Zhou, Xiaojin Wu, Miao Miao, Tao You, Xiao Ma, Haiping Dai

Blood (2024) 144 (Supplement 1): 4893.

https://doi.org/10.1182/blood-2024-207338

Published: 2024

Journal Articles

Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial

Yan-yan Li, Hai-xia Zhou, Si-man Huang, Chao-Ling Wan, Ming-zhu Xu, Wen-jie Gong, Chong-Sheng Qian, De-pei Wu, Haiping Dai, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2023-185312

Published: 2023

Journal Articles

Venetoclax Combined with Hypomethylation Agents As Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia - Priliminary Results from a Real World Study in China

Haiping Dai, Jia Chen, Xiebing Bao, Depei Wu, Suning Chen

Blood (2023) 142 (Supplement 1): 1518.

https://doi.org/10.1182/blood-2023-189654

Published: 2023

Journal Articles

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Blood (2023) 142 (Supplement 1): 889.

https://doi.org/10.1182/blood-2023-172615

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of Zefamenib combined with chemotherapy or targeted Agents in patients with Acute Myeloid Leukemia

Ivosidenib combined with venetoclax and azacitidine for the treatment of newly diagnosed IDH1-mutant Acute Myeloid Leukemia: A prospective, two cohorts, multicenter study

Clinical features and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia: A 15-year retrospective study

Safety and efficacy of low-intensity chemotherapy combined with sequential blinatumomab and inotuzumab ozogamicin immunotherapy in newly diagnosed B-ALL patients unfit/fit-declined for intensive chemotherapy: A prospective, open-label, single-arm Phase II trial in progress

Auto-HSCT combined with blinatumomab as an allo-HSCT-sparing strategy in newly diagnosed B-ALL: Phase II trial results

Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFβ::MYH11(+) acute myeloid leukemia

Venetoclax, cladribine plus low-dose cytarabine for relapsed/refractory Acute Myeloid Leukemia: A multicenter, randomized phase II Study

Bgb-11417: A novel BCL2 inhibitor with robust antileukemic activity in T-cell acute lymphoblastic leukemia, alone or with vincristine

Enhanced homing and infiltration capabilities of CI9 cells improve treatment efficacy for T-cell acute lymphoblastic leukemia with extramedullary involvement

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial

Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial

Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Safety and Efficacy of Blinatumomab and Auto-HSCT “Sandwich” Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia

Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Sitagliptin for Prophylaxis of aGVHD in Alternative Donor Transplantations: Updated Results of 2 Years Follow-up of a Superiority, Randomized Controlled Phase III Trial

Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial

Venetoclax Combined with Hypomethylation Agents As Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia - Priliminary Results from a Real World Study in China

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only